Forbes Medi-Tech Initiates Toxicity Study on FM-VP4

Forbes Medi-Tech has commenced a 90-day toxicity study for its cholesterol-lowering drug, FM-VP4.

This study is required to support an extended U.S. Phase II human trial planned for later this year. Results from an earlier 28-day European trial of FM-VP4 suggest that low-density lipoprotein cholesterol levels may continue to decrease when FM-VP4 is given to patients for longer than four weeks and that optimal efficacy may not have been achieved.